伊伐布雷定联合复方血栓通胶囊治疗冠心病心肌梗死的临床疗效及对心功能、心肌损伤的影响

Clinical Efficacy of Ivabradine Combined with Compound Thromboxone Capsules in the Treatment of Coronary Heart Disease Myocardial Infarction and Analysis of its Influence on Cardiac Function and Myocardial Injury

目的:探析伊伐布雷定+复方血栓通胶囊中西联合疗法应用于冠心病心肌梗死(acute myocardial infarction,AMI)临床效果及对其心功能、心肌损伤的影响。方法:选取2020年1月—2021年2月商丘市中医院收治的106例冠心病AMI患者作为研究对象,根据治疗方案不同将患者分为观察组(n=53)和对照组(n=53)。对照组采用单纯伊伐布雷定治疗,观察组采用伊伐布雷定联合复方血栓通胶囊。对比两组患者治疗前后4周心功能指标[左心室射血分数(left ventricular end diastolic,LVEF)、左心室舒张末期内径(left ventricular end-diastolic dimension,LVEDD)及左室收缩末内径(left ventricular end systolic diameter,LVESD)、临床疗效、心肌损伤指标(肌酸激酶同工酶(creatine kinase-MB,CK-MB)、心肌肌钙蛋白Ⅰ(cardiac troponin I,cTnI)。结果:观察组综合有效率(96.23%)明显高于对照组综合有效率(83.02%),差异有统计学意义(χ^(2)=4.970,P<0.05);治疗后,两组患者CK-MB、c TnI水平明显下降,且观察组CK-MB、cTnI水平明显低于对照组,差异有统计学意义(t=9.430、24.161,P<0.05);治疗后,两组患者LVEDD、LVESD水平明显下降,LVEF出现明显上升,且观察组LVEDD、LVESD水平明显低于对照组,而LVEF明显高于对照组,差异有统计学意义(t=4.236、6.590、8.139,P<0.05)。结论:伊伐布雷定+复方血栓通胶囊应用于冠心病AMI临床效果显著,可有效改善患者心功能指标,促进心肌损伤康复。

Objective:To investigate the clinical effects of combined Chinese and Western therapies(ivabradine+compound thromboxone capsule)on myocardial infarction(AMI)in coronary artery disease and its effects on cardiac function and myocardial injury.Methods:One hundred and six patients with coronary heart disease AMI admitted to the hospital from January 2020 to February 2021 were selected and divided into observation group and control group according to the treatment plan,with 53 cases in each group.The control group was treated with ivabradine alone,and the observation group was treated with ivabradine combined with compound thromboxane capsules.The cardiac function indexes(left ventricular ejection fraction[LVEF],left ventricular end-diastolic internal diameter[LVEDD]and left ventricular end-systolic internal diameter[LVESD]),clinical efficacy,and myocardial injury indexes(creatine kinase isoenzyme[CK-MB],cardiac troponin I[cTnI])before and after 4 weeks of treatment were compared between the two groups.Results:The combined effective rate of the observation group(96.23%)was significantly higher than that of the control group(83.02%),and the difference was statistically significant(χ^(2)=4.970,P<0.05).After treatment,the levels of CK-MB and cTnI decreased significantly in both groups,and the levels of CK-MB and c TnI in the observation group were significantly lower than those in the control group,with statistically significant differences(t=9.430,24.161,P<0.05).After treatment,LVEDD and LVESD levels decreased significantly and LVEF increased significantly in both groups,and LVEDD and LVESD levels in the observation group were significantly lower than those in the control group,while LVEF was significantly higher than that in the control group,with statistically significant differences(t=4.236,6.590,8.139,P<0.05).Conclusion:Ivabradine+compound thromboxone capsule is clinically effective in AMI of coronary heart disease,which can effectively improve patients’cardiac function index and promote recovery from myocardial injury.